This article reviews the neuroprotective effects of monoamine oxidase inhibitors (MAOIs), such as selegiline and rasagiline, in the context of age-dependent neurodegenerative disorders like Parkinson’s and Alzheimer’s diseases. The review highlights that MAOIs work by reducing oxidative stress, stabilizing mitochondria, enhancing neurotrophic factors like nerve growth factor (NGF) and brain-derived
